跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 20,836 条关于
“HARMONi-6/AK112-306”
全部
20,836
临床试验
10,850
药物
3,596
机构
1,335
资讯
5,055
去年
Akeso Completes Patient Enrollment in Phase III Trial Comparing Ivonescimab for First-Line Squamous NSCLC Treatment
6天前
Ivonescimab Beats Pembrolizumab on Overall Survival in First-Line PD-L1-Positive NSCLC: HARMONi-2 Data at WCLC 2026
2年前
Summit Therapeutics Completes Enrollment in Phase III HARMONi Trial and Receives FDA Fast Track Designation for Ivonescimab
去年
Akeso's Ivonescimab Enrolls First Patient in Phase 3 Biliary Tract Cancer Trial
去年
Akeso's Ivonescimab Enrolls First Patient in Phase 3 Biliary Tract Cancer Trial
2年前
Ivonescimab Shows Promise in Combination Therapies for CRC, TNBC, and HNSCC
去年
Ivonescimab Demonstrates Superior PFS Over Pembrolizumab in PD-L1 Positive NSCLC
去年
Summit Therapeutics Advances Ivonescimab Program with Pfizer Collaboration and Phase III Trial Progress in NSCLC
去年
Summit Therapeutics' Phase 3 HARMONi Trial Poised for Mid-2025 Readout in Duchenne Muscular Dystrophy
3天前
Updated HARMONi Data at WCLC 2026 Show Durable Overall Survival Benefit for Ivonescimab in EGFR-Mutated NSCLC
第 1 页,共 506 页
上一页
下一页